Indian Angel Network plans investment in around 150 startups

NEW DELHI: Venture capital consortium Indian Angel Network (IAN) is looking to invest in about 150 start-up firms in coming 4-5 years, a co-founder of the investment group said. “We have made six commitments as of now. In next 4-5 years, we have plans to invest in 100-150 firms,” said IAN co- founder Saurabh Srivastava. He said there is no shortage of funds at IAN and investors are looking at right opportunities. “We have funded in range of half a million to a million. Some has been to the tune of 3…

Read More

Shell plans 400 job cuts at Dutch projects and technology department

 Royal Dutch Shell Plc plans to cut more than 400 jobs in the Netherlands, mainly at its major projects and energy technology operations, as the oil giant shifts its business model in response to lower oil prices, according to an internal document seen by Reuters. The world’s second-largest oil company by market capitalization said in a statement responding to questions from Reuters that “approximately 400 (staff) are potentially at risk of redundancy during the last quarter of 2017/first half of 2018”. That represents around a quarter of the roles at…

Read More

US News ranks best diet plans for 2017

An estimated tens of millions of Americans will hit the gym and purge their pantries this month in hopes of slashing pounds and improving their health for the new year. But the diet plan they pick may influence their success. That’s where U.S. News & World Report’s Best Diets list aims to help. The consumer advice website has released its annual report on what it deems the 38 best diet plans across nine categories, including those programs that are ideal for fast weight loss and healthy eating, as well as…

Read More

Austrian biotech plans Zika vaccine clinical trials in 12 months

An Austrian biotech company working with the Institut Pasteur said on Tuesday it planned to start clinical trials with an experimental Zika vaccine in the next 12 months, marking a further acceleration of research in the field. Themis Bioscience has signed a licence deal with the French research institute giving it extensive rights to the Zika vaccine candidate, which is based on established measles vaccine technology. More than a dozen small biotech firms and other organisations are working on vaccines against mosquito-borne Zika, which has been linked to birth defects…

Read More